Open Access Open Access  Restricted Access Subscription or Fee Access

Specimen validity testing in urine drug monitoring of medications and illicit drugs: Clinical implications

Kenneth L. Kirsh, PhD, Paul J. Christo, MD, MBA, Howard Heit, MD, Katherine Steffel, PharmD, Steven D. Passik, PhD

Abstract


Objective: To discuss the importance of specimen validity testing (SVT) in urine drug testing (UDT) and the clinical role it plays in identifying efforts to subvert the UDT process.

Methods: A discussion of the clinical impact of SVT is presented.

Results: A discussion of pH, specific gravity, creatinine, and oxidation for monitoring the adulteration of UDT samples is presented along with the clinical significance of such tests.

Significance: SVT has a significant place in healthcare efforts to measure patient adherence, behavior, and honesty in communication with clinicians. SVT is typically ordered by treating clinicians who use the results to make therapeutic decisions regarding specific medical problems of their patient, including those related to medication and illicit drug use. In the absence of SVT, a healthcare provider may fail to identify a patient's adulteration of their urine sample in an attempt at deceiving the provider. Moreover, the presence of some underlying medical conditions may obfuscate the UDT results.


Keywords


urine drug testing, specimen validity, behavior, adulteration

Full Text:

PDF

References


Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10: 113-130.

Federation of State Medical Boards: Model policy on the use of opioid analgesics in the treatment of chronic pain. Washington, DC: Federation of State Medical Boards. July 2013. Available at http://www.fsmb.org. Accessed October 13, 2013.

Gourlay DL, Heit HA, Caplan YH: Urine Drug Testing in Clinical Practice: The Art and Science of Patient Care. California Academy of Family Physicians, 2010: 6-10. Available at http://www.pharmacogroup.com/udt/udt5.pdf. Accessed October 13, 2013.

Lin CN, Strathmann FG: Elevated urine zinc concentration reduces the detection of methamphetamine, cocaine, THC and opiates in urine by EMIT. J Anal Toxicol. 2013; 37(9): 665-669.

Venkatratnam A, Lents NH: Zinc reduces the detection of cocaine, methamphetamine, and THC by ELISA urine testing. J Anal Toxicol. 2011; 35(6): 333-340.

Karch SB (ed.): Drug Abuse Handbook, 2nd ed. Boca Raton, FL: CRC Press, Taylor and French Group, 2007: 843 p.

NVSS: National Vital Statistics System, 1999-2008; Automation of Reports and Consolidated Orders System (ARCOS) of the Drug Enforcement Administration (DEA), 1999-2010; Treatment Episode Data Set, 1999-2009, NVSS. Available at http://www.cdc.gov/nchs/nvss.htm. Accessed October 13, 2013.

Centers for Disease Control and Prevention (CDC): Opioids drive continued increase in opioid overdose deaths. Press Release February 20, 2013. Available at http://www.cdc.gov/media/releases/2013/p0220_drug_overdose_deaths.html. Accessed July 15, 2013.

Office of Inspector General (OIG): Spotlight on drug diversion. Available at https://oig.hhs.gov/newsroom/spotlight/2013/diversion.asp. Accessed July 10, 2013.

Substance Abuse and Mental Health Services Administration (SAMHSA): New report shows treatment admissions for abuse of prescription pain relievers have risen 430 percent from 1999- 2009. http://www.samhsa.gov/newsroom/advisories/1112074117.aspx. Accessed September 23, 2012.

Wasan AD, Butler SF, Budman SH, et al.: Psychiatric history and psychological adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007; 23(4): 307-315.

Passik SD, Kirsh KL, Whitcomb LA, et al.: Monitoring outcomes during long-term opioid therapy for non-cancer pain: Results with the pain assessment and documentation tool. J Opioid Manage. 2005; 1(5): 257-266.

Katz N, Sherburne S, Beach M, et al.: Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003; 97: 1097-1102.

Michna E, Jamison RN, Pham LD, et al.: Urine toxicology screening among chronic pain patients on opioid therapy: Frequency and predictability of abnormal findings. Clin J Pain. 2007; 23: 173-179.

Quest: Three in five Americans misuse their prescription drugs, finds national study of prescription medication lab testing. Quest diagnostics report, April 2012. Available at http://ir.questdiagnostics.com/phoenix.zhtml?c=82068&p=irolnewsArticle_pf&id=1688624. Accessed July 13, 2013.

Gourlay DL, et al.: Urine Drug Testing in Clinical Practice, 5th ed. The John Hopkins University School of Medicine, 2012.

Jaffee WB, Trucco E, Teter C, et al.: Ensuring validity in urine drug testing. Psychiatric Services. 2008; 59: 140-142.

Reisfield GM, Goldberger BA, Bertholf RL: False positive and false-negative test results in clinical urine drug testing. Bioanalysis. 2009; 1(5): 937-952.

Substance Abuse and Mental Health Services Administration: Clinical drug testing in primary care. Technical Assistance Publication (TAP) 32. 2012. HHS Publication No. SMA 12-4668. Rockville, MD: Substance Abuse and Mental Health Services Administration.

Nafziger AN, Bertino JS: Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain. 2009; 25(1): 73-79.

Peppin JF, Passik SD, Couto JE, et al.: Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. Pain Med. 2012; 13(7): 886-896.

Cook JD, Strauss KA, Caplan YH, et al.: Urine pH: The effects of time and temperature after collection. J Anal Toxicol. 2007; 31(8): 486-496.

Cook JD, Caplan YH, LoDico CP, et al.: The characterization of human urine for specimen validity determination in workplace drug testing: A review. J Anal Toxicol. 2000; 24: 579-588.

Paul BD, Dunkley CS: Specimen validity testing—Effects of oxidizing agents on drugs in urine and procedures for detection. Forensic Sci Rev. 2007; 19: 29-47.

Price JW: Creatinine normalization of workplace urine drug tests: Does it make a difference? J Addict Med. 2013; 7(2): 129-132.

Christo PJ, Manchikanti L, Ruan X, et al.: Urine drug testing in chronic pain. Pain Physician. 2011; 14: 123-43.

Baiker C, Serrano L, Lindner B: Hypochlorite adulteration of urine causing decreased concentration of delta-9-THCCOOH by GC/MS. J Anal Toxicol. 1994; 18: 101-103.

Schwarzhoff R, Cody JT: The effects of adulterating agents on FPIA analysis of urine for drugs of abuse. J Anal Toxicol. 1993; 17: 14-17.

Wu A, Bristol B, Sexton K, et al.: Adulteration of urine by Urine Luck. Clin Chem. 1999; 45: 1051-1057.

Medical Advisory Secretariat (MAS): Optimum methadone compliance testing: An evidence-based analysis. Ontario Health Technology Assessment Series. 2006; 6(21): 1-54.

Owen GT, Burton AW, Schade CM, et al.: Urine drug testing: Current recommendations and best practices. Pain Physician. 2012; 15: ES119-ES133.

Clancy Z, O'Connell K, Couto J: The use of urine drug monitoring in chronic opioid therapy: An analysis of current clinician behavior. J Opioid Manage. 2013; 9(2): 121-127.

Federal Register: Procedures for transportation workplace drug and alcohol testing programs: Final rule. 73 Federal Register 123, June 25, 2008: 35961-35962.

Cone EJ, Caplan YH, Moser F, et al. Normalization of urinary drug concentrations with specific gravity and creatinine. J Anal Toxicol. 2009; 33(1): 1-7.




DOI: https://doi.org/10.5055/jom.2015.0252

Refbacks

  • There are currently no refbacks.